Uterine Cancer

  • S. D. Yamada
  • S. E. Waggoner

Abstract

In 2002 it is estimated that endometrial carcinoma, the most common gynecologic malignancy in North America, will comprise 6 % of all new cancer cases in women. The incidence of uterine cancer (39,300 estimated cases in 2002) and deaths attributable to uterine cancer (6600 estimated in 2002) have remained relatively stable over the past 20 years [1]. Endometrial cancer is primarily a disease of postmenopausal women, with the incidence peaking between the ages of 55 and 65. Among white women, the incidence of uterine cancer is about twice that of African-American women; however, African-American women are more likely to die from this disease; the 5-year survival rate between 1989 and 1996 was 86% for Caucasian women as compared to 57% for African-American women [2]. This difference in survival may reflect the preponderance of tumors in African-Americans with unfavorable histology, higher grade and, possibly, more advanced stage at diagnosis [3].

Keywords

Estrogen Adenocarcinoma Cyclophosphamide Osteosarcoma Etoposide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Greenlee RT, Hill-Harmon MB, Murray T, Thun M (2001) Cancer statistics, 2001. CA Cancer J Clin 51:15–36PubMedCrossRefGoogle Scholar
  2. 2.
    Greenlee RT, Hill-Harmon MB, Murray T, Thun M (2001) Cancer statistics, 2001. CA Cancer J Clin 51:35CrossRefGoogle Scholar
  3. 3.
    Connell PP, Rotmensch J, Waggoner SE, Mundt AJ (1999) Race and clinical outcome in endometrial carcinoma. Obstet Gynecol 94:713–720PubMedCrossRefGoogle Scholar
  4. 4.
    Kurman RJ, Kaminski PF, Norris HJ (1985) The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer 56:403–412PubMedCrossRefGoogle Scholar
  5. 5.
    Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D (1995) Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85:304–313PubMedCrossRefGoogle Scholar
  6. 6.
    Weiderpass E, Adami H-O, Baron JA, Magnusson C, Bergström R, Lindgren A, Correia N, Persson I (1999) Risk of endometrial cancer following estrogen replacement with and without progestins, J Natl Cancer Inst 91:1131–1137PubMedCrossRefGoogle Scholar
  7. 7.
    Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfversward C, Skoog L, Somell A, Theve T, Wilking N (1989) Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1:117–120PubMedCrossRefGoogle Scholar
  8. 8.
    Fisher B, Constantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527–537PubMedCrossRefGoogle Scholar
  9. 9.
    Rayter, Shepherd J, Gazrt JC (1993) Tamoxifen and endometrial lesions. Lancet 343:1124CrossRefGoogle Scholar
  10. 10.
    Grimes DA, Economy KE (1995) Primary prevention of gynecologic cancers. Am J Obstet Gynecol 172:227–235PubMedCrossRefGoogle Scholar
  11. 11.
    Cherkis RC, Patten SF Jr, Andrews TJ, Dickinson JC, Patten FW (1988) Significance of normal endometrial cells detected by cervical cytology. Obstet Gynecol 71:242–244PubMedGoogle Scholar
  12. 12.
    Cherkis RC, Patten SF Jr, Dickinson JC, Dekanich AS (1987) Significance of atypical endometrial cells detected by cervican cers. AmJ Obstet Gynecol 69:786–789Google Scholar
  13. 13.
    Chambers JT, Chambers SK (1992) Endometrial sampling: When? Where? Why? With what? Clinical Obstet Gynecol 35: 28–39CrossRefGoogle Scholar
  14. 14.
    Sutton GP, Brill L (1987) Malignant papillary lesions of the endometrium. Gynecol Oncol 27:294–304PubMedCrossRefGoogle Scholar
  15. 15.
    Campbell K, Nuss RC, Benrubi GI (1988) An evaluation of the clinical staging of endometrial cancer. J of Rep Med 33: calOGoogle Scholar
  16. 16.
    Yamada SD, Burger RA, Brewster WR, Anton D, Kohler MF, Monk BJ (2000) Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer 88:278:2–6Google Scholar
  17. 17.
    Concepcion D, Arrastia MD, Fruchter RG, Clark M, Maiman M, Remy JC, Macasaet M, Gates EJ, Di Maio T, Marzec T (1997) Uterine carcinosarcomas: incidence and trends in management and survival. Gynecol Oncol 65:158–163CrossRefGoogle Scholar
  18. 18.
    Pecorelli S, Creasman (1998) WT FIGO annual report on the results of treatment in gynaecological cancer. J Epidemiol Biostat 23:45Google Scholar
  19. 19.
    Chuang JT, Van Velden DJ, Graham JB (1970) Carcinosarcoma and mixed mesodermal tumor of the uterine corpus. Review of 49 cases. Obstet Gynecol 35:769–780PubMedGoogle Scholar
  20. 20.
    Dinh TV, Slavin RE, Bhagavan BS, Hannigan EV, Tiamson EM, Yandell RB (1989) Mixed mullerian tumors of the uterus: a clinicopathologic study. Obstet Gynecol 74: 388–392PubMedGoogle Scholar
  21. 21.
    Kosary CL (1994) FIGO stage, histology, histologic grade, age, and race as prognostic factors in determining survival for cancers of the female gynecologic system: an analysis of 1973–1987 SEER cases of cancers of the endometrium, cervix, ovary, vulva and vagina. Sem Surg Oncol 10:31–46CrossRefGoogle Scholar
  22. 22.
    Morrow CP, Bundy BN, Kurman RJ et al (1991) Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 40:55–65PubMedCrossRefGoogle Scholar
  23. 23.
    Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB (1987) Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group Study. Cancer 60:2035–2041PubMedCrossRefGoogle Scholar
  24. 24.
    Turner DA, Gershenson DM, Atkinson N, Sneige N, Wharton AT (1989) The prognostic significance of peritoneal cytology for stage I endometrial cancer. Obstet and Gynecol 74: 775–780Google Scholar
  25. 25.
    Kadar N, Homesley HD, Malfetano JH (1992) Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. Gynecol Oncol 46:145–149PubMedCrossRefGoogle Scholar
  26. 26.
    Goff BA, Kato D, Schmidt RA, Ek M, Ferry JA, Muntz HG, Cain JM, Tamimi HK, Figge DC, Greer, BE (1994) Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 54:264–268PubMedCrossRefGoogle Scholar
  27. 27.
    Nyholm HC, Nielsen AL, Lyndrup J, Norup P, Thorpe SM (1992) Biochemical and immunohistochemical estrogen and progesterone receptors in adenomatous hyperplasia and endometrial carcinoma: correlations with stage and other clinicopathologic features. Am J Obstet Gynecol 167: 1334–1342PubMedGoogle Scholar
  28. 28.
    Sood AK, Buller RE, Burger RA, Dawson JD, Sorosky JI, Berman M (1997) Value of pre-operative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet Gynecol 90:441–447PubMedCrossRefGoogle Scholar
  29. 29.
    Orr J, Holiman JL, Orr PF (1997) Stage I corpus cancer: is teletherapy necessary? Am J Obstet Gynecol 176:777–778PubMedCrossRefGoogle Scholar
  30. 30.
    Aalders J, Abeler V, Kolstad P, Onsrud M (1980) Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study ou tco me. Obstet Gynecol 90:441–447Google Scholar
  31. 31.
    Irwin C, Levin W, Fyles A, Pintilie M, Manchul L, Kirkbride P (1998) The role of adjuvant radiotherapy in carcinoma of the endometrium — results in 550 patients with pathologic stage I disease. Gynecol Oncol 70:247–254PubMedCrossRefGoogle Scholar
  32. 32.
    Roberts JA, Brunette VL, Keys HM, Zaino R, Spirtos NM, Bloss JD, Pearlman A, Maiman MA, Bell JG (1998) A phase III randomized study of surgery vs surgery plus adjunctive radiation therapy in intermediate-risk endometrial adenocarcinoma (GOG No. 99) (abstract). Gynecol Oncol 68:135Google Scholar
  33. 33.
    Calais G, LeFloch O, Descamps P, Vitu L, Lansac J (1991) Radical hysterectomy for stage I and II endometrial carcinoma: a retrospective analysis of 179 cases. Int J Radiat Oncol Biol Phys 20:677–683PubMedCrossRefGoogle Scholar
  34. 34.
    Reisinger SA, Staros EB, Mohiuddin M (1991) Survival and failure analysis in stage II endometrial cancer using the revised 1988 FIGO staging system. Int J Radiat Oncol Biol Phys 21:1027–1032PubMedCrossRefGoogle Scholar
  35. 35.
    Calais G, Vitu L, Descamps P, Body G, Reynaud-Bougnoux A, Lansac J, Bougnoux P, LeFloch O (1990) Preoperative or postoperative brachytherapy for patients with endometrial carcinoma stage I and II. Int J Radiat Biol Phys 19:523–527CrossRefGoogle Scholar
  36. 36.
    Podczaski ES, Kaminski P, Manetta A, Louk D, Andrews C, Larson J, DeGeest K, Mortel R (1989) Stage II endometrial carcinoma treated with external beam radiotherapy, intracavitary application of cesium, and surgery. Gynecol Oncol 35:251–254PubMedCrossRefGoogle Scholar
  37. 37.
    Larson DM, Copeland LJ, Gallager HS, Wharton JT, Gershenson DM, Edwards CL, Malone JM, Rutledge FN (1987) Prognostic factors in stage II endometrial carcinoma. Cancer 60:1358–1361PubMedCrossRefGoogle Scholar
  38. 38.
    Lanciano RM, Curran WJ, Greven KM, Fanning J, Stafford P, Randall ME, Hanks GE (1990) Influence of grade, histologic subtype, and timing of radiotherapy on outcome among patients with stage II carcinoma of the endometrium. Gynecol Oncol 39:368–373PubMedCrossRefGoogle Scholar
  39. 39.
    Surwit EA, Fowler WC, Rogoff EE (1978) Stage II carcinoma of the endometrium. An analysis of treatment. Obstet Gynecol 52:97–99PubMedGoogle Scholar
  40. 40.
    Childers JM, Brzechffa PR, Hatch KD, Surwit EA (1993) Laparoscopically assisted surgical staging (LASS) of endometrial cancer. Gynecol Oncol 51:33–38PubMedCrossRefGoogle Scholar
  41. 41.
    Gemignani ML, Curtin JP, Zelmanovich J, Patel DA, Venkatramen E, Barakat RR (1999) Laparoscopic assisted vaginal hysterectomy for endometrial cancer: clinical outcomes and hospital charges. Gynecol Oncol 73:5–11PubMedCrossRefGoogle Scholar
  42. 42.
    Chan JK, Lin YG, Monk BJ, Tewari K, Bloss JD (2001) Vaginal hysterectomy as primary treatment of endometrial cancer in medically compromised women. Obstet Gynecol 97: 707–711PubMedCrossRefGoogle Scholar
  43. 43.
    Cornelison TL, Trimble EL, Kosary CL (1999) SEER data, corpus uteri cancer: treatment trends versus survival for FIGO stage II, 1988–1994. Gynecol Oncol 74:350–355PubMedCrossRefGoogle Scholar
  44. 44.
    Kilgore LC, Partridge EE, Alvarez RD, Austin JM, Shingleton HM, Noojin F, Conner W (1995) Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic lymph node sampling. Gynecol Oncol 56: 29–33PubMedCrossRefGoogle Scholar
  45. 45.
    Belinson JL, Lee KR, Badger GJ, Pretorius RG, Jarrell MA (1992) Clinical stage I adenocarcinoma of the endometrium-analysis of recurrences and the potential benefit of staging lymphadenectomy. Gynecol Oncol 44:17–23PubMedCrossRefGoogle Scholar
  46. 46.
    Greven KM, Curran WJ, Whittington R, Fanning J, Randall ME, Wilder J, Peters AJ (1989) Analysis of failure patterns in stage III endometrial carcinoma and therapeutic implications. Int J Radiat Oncol Biol Phys 17:35–39PubMedCrossRefGoogle Scholar
  47. 47.
    Heath R, Rosenman J, Varia M, Walton L (1988) Peritoneal fluid cytology in endometrial cancer: its significance and the role of chromic phosphate (32P) therapy. Int J Radiat Oncol Biol Phys 15:815–822PubMedCrossRefGoogle Scholar
  48. 48.
    Martinez A, Schray M, Podratz K et al (1989) Postoperative whole abdominopelvic irradiation for patients with highrisk endometrial carcinoma. Int J Radiat Oncol Biol Phys 17: 371–377PubMedCrossRefGoogle Scholar
  49. 49.
    Smith RS, Kapp DS, Chen Q, Teng NN (2000) Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy. Int J Radiat Oncolgy Biol Phys 48:767–778CrossRefGoogle Scholar
  50. 50.
    Potish RA (1989) Abdominal radiotherapy for cancer of the uterine cervix and endometrium. Int J Radiat Oncol Biol Phys 16:1453–1458PubMedCrossRefGoogle Scholar
  51. 51.
    Loeffler JS, Rosen EM, Niloff JM et al (1988) Whole abdominal irradiation for tumors of the uterine corpus. Cancer 61: 1332–1335PubMedCrossRefGoogle Scholar
  52. 52.
    Mundt AJ, Murphy KT, Rotmensch J, Waggoner SE, Yamada SD, Connell PP (2001) Surgery and postoperative radiation therapy in FGIO stage IIIC endometrial carcinoma. Int J Radiat Oncol Biol Phys 50:1154–1160PubMedCrossRefGoogle Scholar
  53. 53.
    Bristow RE, Zerbe MJ, Rosenshein NB, Grumbine FC, Montz FJ (2000) Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol Oncol 78:83–84CrossRefGoogle Scholar
  54. 54.
    Barakat RR, Goldman NA, Patel DA, Venkatraman ES, Curtin JP (1999) Pelvic exenteration for recurrent endometrial cancer. Gynecol Oncol 75:99–102PubMedCrossRefGoogle Scholar
  55. 55.
    Morris M, Alvarez RD, Kinney WK, Wilson TO (1996) Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. Gynecol Oncol 60:288–291PubMedCrossRefGoogle Scholar
  56. 56.
    Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta A, Soper JT, Given FT (1999) Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 17: 1736–1744PubMedGoogle Scholar
  57. 57.
    Ball HG, Blessing JA, Lentz SS et al (1996) A phase II trial of Taxol in advanced and recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 62:278–281PubMedCrossRefGoogle Scholar
  58. 58.
    Thigpen T, Blessing J, Homesley H et al (1993) Phase III trial of doxorubicin ± cisplatin in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 12:261Google Scholar
  59. 59.
    Kato DT, Ferry JA, Goodman A, Sullinger J, Scully RE, Goff BA, Fuller AF, Rice LW (1995) Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases. Gynecol Oncol 59:384–389PubMedCrossRefGoogle Scholar
  60. 60.
    Grice J, Ek M, Greer B, Koh W, Muntz HG, Cain J, Tamimi H, Stelzer K, Figge D, Goff BA (1998) Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients. Gynecol Oncol 69:69–73PubMedCrossRefGoogle Scholar
  61. 61.
    Bristow RE, Asrari F, Trimble EL, Montz FJ (2001) Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (stage I-III) disease. Gynecol Oncol 81:279–286PubMedCrossRefGoogle Scholar
  62. 62.
    Bancher-Todesca D, Neunteufel W, Williams KE, Prainsack D, Breitenecker G, Friedlander ML, Hacker NF (1998) Influence of postoperative treatment on survival in patients with uterine papillary serous carcinoma. Gynecol Oncol 71:344–347PubMedCrossRefGoogle Scholar
  63. 63.
    Lim P, Al Kushi A, Gilks B, Wong F, Aquino-Parsons C (2001) Early stage uterine papillary serous carcinoma of the endometrium. Effect of adjuvant whole abdominal radiotherapy and pathologic parameters on outcome. Cancer 91: 752–757PubMedCrossRefGoogle Scholar
  64. 64.
    Bristow RE, Duska LR, Montz FJ (2001) The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. Gynecol Oncol 81:92–99PubMedCrossRefGoogle Scholar
  65. 65.
    Zanotti KM, Belinson JL, Kennedy AW, Webster KD, Markman M (1999). The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma. Gynecol Oncol 74:272–277PubMedCrossRefGoogle Scholar
  66. 66.
    Price FV, Chambers SK, Carcangiu ML, Kohorn El, Schwartz PE, Chambers JT (1993) Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC). Gynecol Oncol 51:383–389PubMedCrossRefGoogle Scholar
  67. 67.
    Knocke TH, Weitmann HD, Kucera H, Kolbl H, Pokrajac B, Potter R (1999) Results of primary and adjuvant radiotherapy in the treatment of mixed Mullerian tumors of the corpus uteri. Gynecol Oncol 73:389–395PubMedCrossRefGoogle Scholar
  68. 68.
    Knocke TH, Kucera H, Dorfler D, Pokrajac B, Potter R (1998) Results of postoperative radiotherapy in the treatment of sarcoma of the corpus uteri. Cancer 83:1972–1979Google Scholar
  69. 69.
    Thigpen JT, Blessing JA, Orr JW, DiSaia PJ (1986) Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group study. Cancer Treat Rep 70: 271–274PubMedGoogle Scholar
  70. 70.
    Sutton G, Brunette VL, Kilgore L, Soper JT, McGehee R, Olt G, Lentz SS, Sorosky J, Hsiu JG (2000) A phase III trial of ifosphamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 79:147–153PubMedCrossRefGoogle Scholar
  71. 71.
    Muss HB, Bundy B, DiSaia PJ, Homesely HD, Fowler WC, Creasman W, Yordan E (1985) Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer 55:1648–1653PubMedCrossRefGoogle Scholar
  72. 72.
    Sutton GP, Blessing JA, Barrett RJ, McGehee R (1992) Phase II trial of ifosphamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Am J Obstet Gynecol 166:556–559PubMedGoogle Scholar
  73. 73.
    Sutton G, Blessing JA, Malfetano JH (1996) Ifosphamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 62:226–229PubMedCrossRefGoogle Scholar
  74. 74.
    Thigpen JT, Blessing JA, Wilbanks GD (1986) Cisplatin as second-line chemotherapy in the treatment of advanced or recurrent leiomyosarcoma of the uterus. A phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 9: 18–20PubMedCrossRefGoogle Scholar
  75. 75.
    Thigpen JT, Blessing JA, Homesley H, Creasman WT, Sutton G (1989) Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 33:68–70PubMedCrossRefGoogle Scholar
  76. 76.
    Edmonson JH, Krook JE, Hilton JF, Malkasian GD, Everson LK, Jefferies JA, Mailliard JA (1987) Randomized phase II studies of cisplatin and a combination of cyclophos-phamide-doxorubicin-cisplatin (CAP) in patients with progestin-refractory advanced endometrial carcinoma. Gynecol Oncol 28:20–24PubMedCrossRefGoogle Scholar
  77. 77.
    Sutton GP, Blessing JA, DeMars LR, Moore D, Burke TW (1996) A phase II Gynecologic Oncology Group trial of ifosphamide and mesna in advanced or recurrent adenocarcinoma of the endometrium. Gynecol Oncol 63:25–27PubMedCrossRefGoogle Scholar
  78. 78.
    Thigpen JT, Blessing JA, Ball H, Hanjani P, Manetta A, Homesley H (1988) Hexamethylmelamine as first-line chemotherapy in the treatment of advanced or recurrent carcinoma of the endometrium: a phase II trial of the Gynecologic Oncology Group. Gynecol Oncol 31:435–438PubMedCrossRefGoogle Scholar
  79. 79.
    Ball HG, Blessing JA, Lentz SS, Mutch DG (1996) A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 62:278–281PubMedCrossRefGoogle Scholar
  80. 80.
    Thigpen JT, Buchsbaum HJ, Mangan C, Blessing JA (1979) Phase II trial of Adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Cancer Treat Rep 63:21–27PubMedGoogle Scholar
  81. 81.
    Burke TW, Munkarah A, Kavanagh JJ, Morris M, Levenback C, Tornos C, Gershenson DM (1993) Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin. Gynecol Oncol 51:397–400PubMedCrossRefGoogle Scholar
  82. 82.
    Polin EA, Liu PY, Delmore JE, Wilczynski S, Moore DF, Potkul RK, Fine BA, Hannigan EV, Alberts DS (1999) Phase II trial or oral etoposide in recurrent or refractory endometrial adenocarcinoma: a Southwest Oncology Group study. Gynecol Oncol 74:432–435CrossRefGoogle Scholar
  83. 83.
    Moore DH, Blessing JA, Dunton C, Buller RE, Reid GC (1999) Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 75:473–475PubMedCrossRefGoogle Scholar
  84. 84.
    Rose PG, Blessing JA, Lewandowski GS, Creasman WT (1996) A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study. 63: 101–104CrossRefGoogle Scholar
  85. 85.
    Poplin EA, Liu PY, Delmore JE, Wilczynski S, Moore DF, Potkul RK, Fine BA, Hannigan EV, Alberts DS (1999) Phase II oral etoposide in recurrent or refractory endometrial adenocarcinoma: a Southwest Oncology Group study. Gynecol Oncol 74:432–435PubMedCrossRefGoogle Scholar
  86. 86.
    Thigpen JT, Kronmal R, Vogel S, Hynes HE, Nahhas W, Belt RJ, Balcerzak SP, Epstein RB, Costanzi JJ (1987) A phase II trial of vinblastine in patients with advanced or recurrent endometrial carcinoma. A Southwest Oncology Group Study. Am J Clin Oncol 10:429–431PubMedCrossRefGoogle Scholar
  87. 87.
    Thigpen JT, Blessing JA, Lagasse LD, DiSaia PJ, Homesley HD (1984) Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study. Am J Clin Oncol 7:253–256PubMedCrossRefGoogle Scholar
  88. 88.
    Jackson DV, Jobson VW, Homesley HD, Welander C, Hire EA, Pavy MD, Votaw ML, Richards F, Muss HB (1986) Vincristine infusion in refractory gynecologic malignancies. Gynecol Oncol 25:212–216PubMedCrossRefGoogle Scholar
  89. 89.
    Carbone PP, Carter SK (1974) Endometrial cancer: approach to development of effective chemotherapy. Gynecol Oncol 2:348–353PubMedCrossRefGoogle Scholar
  90. 90.
    Trope C, Johnsson JE, Simonsen E, Christiansen H, CavallinStahl E, Horvath G (1984) Treatment of recurrent endometrial carcinoma with a combination of doxorubicin and cisplatin. Am J Obstet Gynecol 149:379–381PubMedGoogle Scholar
  91. 91.
    Pasmantier MW, Coleman M, Silver RT, Mamaril AP, Quiguyan CC, Galindo A (1985) Treatment of advanced endometrial carcinoma with doxorubicin and cisplatin: effects on both untreated and previously treated patients. Cancer Treat Rep 69:539–542PubMedGoogle Scholar
  92. 92.
    Seski JC, Edwards CL, Gershenson DM, Copeland LJ (1981) Doxorubicin and cyclophosphamide chemotherapy for disseminated endometrial cancer. Obstet Gynecol 58:88–91PubMedGoogle Scholar
  93. 93.
    Campora E, Vidali A, Mammoliti S, Ragni N, Conte PF (1990) Treatment of advanced or recurrent adenocarcinoma of the endometrium with doxorubicin and cyclophosphamide. Eur J Gynaecol Oncol 11:181–183PubMedGoogle Scholar
  94. 94.
    Hancock KC, Freedman RS, Edwards CL, Rutledge FN (1986) Cancer Treat Rep 70:789–791PubMedGoogle Scholar
  95. 95.
    Burke TW, Stringer CA, Morris M, Freedman RS, Gershenson DM, Kavanagh JJ, Edwards CL (1991) Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide. Gynecol Oncol 40:264–267PubMedCrossRefGoogle Scholar
  96. 96.
    Dunton CJ, Pfeifer SM, Braitman LE, Morgan MA, Carlson JA, Mikuta JJ (1991) Treatment of advanced and recurrent endometrial cancer with cisplatin, doxorubicin, and cyclophosphamide. Gynecol Oncol 41:113–116PubMedCrossRefGoogle Scholar
  97. 97.
    Dimopoulos MA, Papadimitriou CA, Georgoulias V, Moulopoulos LA, Aravantinos G, Gika D, Karpathios S, Stamatelopoulos S (2000) Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study. Gynecol Oncol 78: 52–57PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • S. D. Yamada
  • S. E. Waggoner

There are no affiliations available

Personalised recommendations